Thus, tissue-specific effects of DNMT3A function, which are beneficial in liver but detrimental in adipose tissue, may result in undesired effects if DNMT3A is targeted systemically to treat obesity-associated diseases. The gene discussed is DNMT3A; the disease is obesity due to melanocortin 4 receptor deficiency.